Subgroup Analysis by Ki-67 and Baseline CgA of the Randomized, Placebo-Controlled Phase 3 Study of Surufatinib in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors (SANET-p)-MedSci.cn

Subgroup Analysis by Ki-67 and Baseline CgA of the Randomized, Placebo-Controlled Phase 3 Study of Surufatinib in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors (SANET-p)

Yu, XJ; Xu, JM; Shen, L; Bai, CM; Li, J; Zhou, ZW; Li, ZP; Li, EX; Yuan, XL; Chi, YHBL; Yin, YM; Lou, WH; Xu, N; Bai, YX; Zhang, T; Xiu, DR; Wang, XW; Guan, S; Fan, SH; Su, WG

PANCREAS, 2022; 51 (3): E43

科室
- - 订阅+
  - 更多科室
工具
服务